新诊断套细胞淋巴瘤患者诊断至治疗间隔的影响
短DTI组无进展生存期(2.5年 vs 4.8年,p<0.0001)和总生存期(7.8年 vs 11.8年,p<0.0001)均显著劣于长DTI组,多因素分析后仍显著。DTI是新诊断MCL的重要预后因素,应与不良临床因素相关并在临床试验中报告。
要点
- 短DTI(0-14天)组无进展生存期2.5年,长DTI(15-60天)组4.8年,差异显著(p<0.0001)。
- 短DTI组总生存期7.8年,长DTI组11.8年,差异显著(p<0.0001)。
- 短DTI组ECOG PS≥2、LDH升高、骨髓受累、B症状、MIPI≥6.2比例更高,接受强化诱导治疗更少。
核心结论
- DTI是新诊断MCL的重要预后因素,与不良临床因素和较差结局强烈相关。
- 所有入组临床试验的新诊断MCL患者均应报告DTI,并采取措施避免选择偏倚。
研究设计与样本
- 研究利用3个大型数据集:爱荷华大学/梅奥诊所SPORE分子流行病学资源、ALL Age Asthma Cohort/CALGB 50403入组患者、以及多中心MCL患者队列。
- 适合观察的患者被排除。
主要发现
- 多数患者(73%,n=797)为长DTI。
- 短DTI组ECOG PS≥2、乳酸脱氢酶升高、骨髓受累、B症状、MIPI≥6.2的比例高于长DTI组,且接受强化诱导治疗的可能性更低。
- 短DTI组中位无进展生存期2.5年 vs 长DTI组4.8年(p<0.0001),中位总生存期7.8年 vs 11.8年(p<0.0001),短DTI组均显著劣于长DTI组。
- 多因素分析中,短DTI与无进展生存期和总生存期的关联仍显著。
临床怎么用
- 作者建议所有入组临床试验的新诊断MCL患者均应报告DTI,并采取措施避免选择偏倚。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on outcomes in MCL using 3 large datasets (1) the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource, (2) patients enrolled in the ALL Age Asthma Cohort/CALGB 50403, and (3) a multisitecohort of patients with MCL. Patients were a priori divided into 2 groups, 0 to 14 days (short DTI) and 15 to 60 days (long DTI). The patients in whom observation was deemed appropriate were excluded. One thousand ninety-seven patients newly diagnosed with MCL and available DTI were included in the study. The majority (73%) had long DTI (n=797). Patients with short DTI had worse eastern cooperative oncology group performance status (ECOG PS ≥2), higher lactate dehydrogenase, bone marrow involvement, more frequent B symptoms, higher MCL International Prognostic Index (MIPI ≥6.2), and were less likely to receive intensive induction therapy than long DTI group. The median progression-free survival (2.5 years vs 4.8 years, p<0.0001) and overall survival (7.8 years vs. 11.8 years, p<0.0001) were significantly inferior in the short DTI group than the long DTI cohort and remained significant for progression-free survival and overall survival in multivariable analysis. We show that the DTI is an important prognostic factor in patients newly diagnosed with MCL and is strongly associated with adverse clinical factors and poor outcomes. DTI should be reported in all the patients newly diagnosed with MCL who are enrolling in clinical trials and steps must be taken to ensure selection bias is avoided.
引用
- Epperla N, Switchenko J, Bachanova V, et al. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023. PMID: 36516079. doi:10.1182/bloodadvances.2022009225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。